Introduction {#s1}
============

Infectious diseases in old populations became an increasingly important global issue ([@B15]). The declining immune system, weakened anatomic and physiologic defenses against pathogens, and medical comorbidities increases the risk for infections in old populations ([@B15]), and results in a high rate of morbidity and mortality in old populations ([@B9]). Since 1980, inﬂuenza and pneumonia ranked among the top 10 causes of death in patients aged over 65 years ([@B10]). Certain optimum drug therapies in younger adults might not be suitable in old populations owing to altered pharmacokinetics and pharmacodynamics ([@B9]). Moreover, increased multidrug-resistant infections occurred in old populations ([@B7]). Thus, effective prevention and treatment strategies based on evidence are critically needed.

Evidence-based practice in old populations relies on clinical trials that were rigorous, transparent, and devoid of bias ([@B21]; [@B1]). Clinical trials provided evidence for clinical practice and were widely regarded as the most crucial evidence source of efficacy and safety ([@B20]). Thus, exploring clinical trials, especially analyzing registered clinical trials, were hot spots to help future clinical practice. Several studies provided comprehensive details about registered trials in several fields ([@B18]; [@B17]; [@B12]; [@B6]); however, there is paucity of published works on the subject of intervention of infectious diseases in old populations. [ClinicalTrials.gov](ClinicalTrials.gov) ([@B4]) provides publicly accessible data of registered clinical trials, affords the most comprehensive source for identifying and tracking completed or ongoing trials, and is the best way to explore the characteristics of registered trials in particular fields ([@B18]; [@B17]; [@B12]; [@B6]). Thus, we performed the current cross-sectional study to investigate the characteristic of registered trials regarding intervention against infectious diseases in old populations.

Methods {#s2}
=======

Reporting Guideline {#s2_1}
-------------------

This was a cross-sectional study, and it was reported according to the reporting guideline STROBE ([@B23]).

Searching of Registered Trials {#s2_2}
------------------------------

[ClinicalTrials.gov](ClinicalTrials.gov) was used to identify registered trials on the intervention of infectious diseases in old populations. We used the advanced search function with the search terms, including viral OR bacterial OR fungal OR parasitic OR infectious disease on May 8^th^, 2019.

Screening Search Trials {#s2_3}
-----------------------

Searched results were screened based on the study types as classified by the [ClinicalTrials.gov](ClinicalTrials.gov). We used the age field as a filter; we included trials designed specifically for adults over age 65 years. Next, we manually reviewed all trials and selected trials regarding intervention of infectious diseases. Trials regarding non-infectious diseases were all excluded.

Data Extraction {#s2_4}
---------------

The following information was extracted: NCT number, title, status, availability of the study results, conditions, interventions, primary funding, primary sponsor, trial phase, enrollment, study design (allocation, intervention model, masking, primary purpose), start date, and location.

Statistical Analysis {#s2_5}
--------------------

Descriptive analyses were used. Primary funding were classified as industry, the National Institutes of Health (NIH), or other funding. The primary sponsors were classified as university, hospital, industry, or other sponsor. Categorical data were reported as frequency and percentage. Continuous variables were reported as median and interquartile range. We excluded missing data from calculations. The differences between counts of categorical variables using the chi-square test or Fisher exact test. All analyses were performed using the SPSS19.0 software. All *P* values of less than 0.05 were taken to be statistically significant.

Results {#s3}
=======

Screening and Included Trials {#s3_1}
-----------------------------

In the initial search, we identified 33 178 registered trials on [ClinicalTrials.gov](ClinicalTrials.gov). After excluding duplicated trials and trials with participants younger than 65 years old, 223 trials remained. After excluding non-interventional trials, we finally identified 138 trials focused on intervention of infectious diseases in old populations ([**Figure 1**](#f1){ref-type="fig"}).

![Flowchart of selection trials.](fphar-11-00942-g001){#f1}

General Characteristics of Included Trials {#s3_2}
------------------------------------------

The characteristics of included trials is shown in [**Table 1**](#T1){ref-type="table"}. Twenty-three trials were started before 2007, 50 trials were started between 2007 and 2012, and 49 trials were started between 2012 and 2017. The status of most trials (N=105, 76.1%) was completed. However, only 31.9% of trials had available results in the database. The lead sponsors were as follows: industry (66.7%), university (14.5%), and hospital (10.1%). North America was the most frequently identified study location (52.9%), followed by Europe (30.4%) and Asia (11.6%). The top four most commonly identified countries were the United States (N=68), Belgium (N=12), Italy (N=7), and Japan (N=7). Most trials were focused on viral pathogens (71.0%), followed by bacterial pathogens (22.5%).

###### 

Characteristics of all included trials.

  Variable             Subgroup                 N (%)
  -------------------- ------------------------ -------------
  Year                                          
                       Prior to 2007            23 (16.7%)
                       2007--2012               50 (36.2%)
                       2012--2017               49 (35.5%)
                       2017--now                16 (11.6%)
  Status                                        
                       Active, not recruiting   13 (9.4%)
                       Completed                105 (76.1%)
                       Recruiting               8 (5.8%)
                       Suspended                1 (0.7%)
                       Terminated               3 (2.2%)
                       Unknown status           6 (4.3%)
                       Withdrawn                2 (1.4%)
  Study results                                 
                       Has results              44 (31.9%)
                       No results available     94 (68.1%)
  Lead sponsor                                  
                       University               20 (14.5%)
                       Hospital                 14 (10.1%)
                       Industry                 92 (66.7%)
                       Other                    12 (8.7%)
  Funded by                                     
                       Industry                 86 (62.3%)
                       NIH                      6 (4.3%)
                       Other                    46 (33.3%)
  Locations                                     
                       Asia                     16 (11.6%)
                       Europe                   42 (30.4%)
                       North America            73 (52.9%)
                       Oceania                  5 (3.6%)
                       South America            2 (1.4%)
  Microbial etiology                            
                       Viral                    98 (71.0%)
                       Bacterial                31 (22.5%)
                       Parasite                 1 (0.7%)
                       Unknown                  8 (5.8%)
  Participants                                  
                       \<=1000                  113 (81.9%)
                       1,000--10,000            20 (14.5%)
                       \>10,000                 5 (3.6%)

Study Designs of Included Trials {#s3_3}
--------------------------------

Study designs of included trials are shown in [**Table 2**](#T2){ref-type="table"}. Most trials were for prevention, and only 10 trials were for treatment. Randomization was commonly used. The most frequently used intervention models were parallel assignment (73.2%) and single group assignment (21.0%). More than half of the trials were masked, and nearly a quarter of the trials involved quadruple masking. Phases of trials were as follows: phase 1 (13.0%), phase 2 (29.7%), phase 3 (21.7%), and phase 4 (23.2%). The estimated median enrollment was 242 participants (interquartile range, 84.5--821.5 participants). Forty-nine trials (35.5%) recruited more than 500 participants, and 25 trials (18.1%) recruited more than 1,000 individuals; another five trials recruited more than 10,000 participants.

###### 

Study design of all included trials.

  Variable             Subgroup                  N(%)
  -------------------- ------------------------- -------------
  Primary purpose                                
                       Prevention                116 (84.1%)
                       Treatment                 10 (7.2%)
                       Other                     12 (8.7%)
  Allocation                                     
                       Randomized                116 (84.1%)
                       Non-randomized            3 (2.2%)
                       Unknown                   19 (13.8%)
  Intervention model                             
                       Crossover assignment      2 (1.4%)
                       Factorial assignment      3 (2.2%)
                       Parallel assignment       101 (73.2%)
                       Sequential assignment     2 (1.4%)
                       Single group assignment   29 (21.0%)
                       Unknown                   1 (0.7%)
  Masking                                        
                       Single                    18 (13.0%)
                       Double                    25 (18.1%)
                       Triple                    12 (8.7%)
                       Quadruple                 34 (24.6%)
                       None (open label)         48 (34.8%)
                       Unknown                   1 (0.7%)
  Phases                                         
                       Phase 1                   18 (13.0%)
                       Phase 1\|phase 2          7 (5.1%)
                       Phase 2                   41 (29.7%)
                       Phase 3                   30 (21.7%)
                       Phase 4                   32 (23.2%)
                       Not applicable            10 (7.2%)
  Enrollment                                     
                       \<=50                     18 (13.0%)
                       50--100                   23 (16.7%)
                       100--500                  47 (34.1%)
                       \>=500                    49 (35.5%)
                       Unknown                   1 (0.7%)

Trials' Characteristics by Funding Source {#s3_4}
-----------------------------------------

Trials were most funded by industry (N=86, 62.3%). Comparison results are shown in [**Table 3**](#T3){ref-type="table"}. Industry-funded trials were mostly started during 2007--2012 whereas non-industry-funded trials mostly began during 2012--2017. Only 13.5% of non-industry-funded trials had available results, compared with 43.0% of industry-funded trials. Industry-funded studies were more focused on preventative interventions than non-industry-funded studies (91.9% *vs*. 71.2%). Parallel assignment (70.9%) and single group assignment (23.3%) were the most frequently used intervention models for industry-funded trials. Parallel assignment (76.9%) and sequential assignment (17.3%) were the most frequently used intervention models for non-industry-funded trials. More non-industry-funded trials were in phase 4 (40.4%), and only 12.8% of industry-funded trials were in phase 4. Industry-funded trials had larger enrollment than non-industry-funded trials. Microbial etiology, allocation, and masking were almost similar. Overall, compared with non-industry funded trials, industry-funded trials had higher percentages of available results, prevention trials, and phase 2 and phase 3 trials, and more lager sample size studies.

###### 

Characteristics and study design of trials according to the primary funding source.

  Variable             Subgroup                   Industry-funded   Non-industry-funded   χ^2^/Fisher   *P* value
  -------------------- -------------------------- ----------------- --------------------- ------------- -----------
  Year                                                                                    12.993        0.005
                       Prior to 2007              13 (15.1%)        10 (19.2%)                          
                       2007--2012                 39 (45.3%)        11 (21.2%)                          
                       2012--2017                 22 (25.6%)        27 (51.9%)                          
                       2017--now                  12 (14.0%)        4 (7.7%)                            
  Status                                                                                  8.031\*       0.178
                       Active, not recruiting     5 (5.8%)          8 (15.4%)                           
                       Completed                  71 (82.6%)        34 (65.4%)                          
                       Recruiting                 3 (3.5%)          5 (9.6%)                            
                       Suspended                  1 (1.2%)          0 (0.0%)                            
                       Terminated                 2 (2.3%)          1 (1.9%)                            
                       Unknown status             3 (3.5%)          3 (5.8%)                            
                       Withdrawn                  1 (1.2%)          1 (1.9%)                            
  Study results                                                                                         
                       Has results                37 (43.0%)        7 (13.5%)                           
                       No results available       49 (57.0%)        45 (86.5%)                          
  Lead sponsor                                                                            127.873\*     \<0.001
                       University                 0 (0.0%)          20 (38.5%)                          
                       Hospital                   0 (0.0%)          14 (26.9%)                          
                       Industry                   86 (100.0%)       6 (11.5%)                           
                       Other                      0 (0.0%)          12 (23.1%)                          
  Primary purpose                                                                         12.512\*      0.001
                       Prevention                 79 (91.9%)        37 (71.2%)                          
                       Treatment                  5 (5.8%)          5 (9.6%)                            
                       Other                      2 (2.3%)          10 (19.2%)                          
  Allocation                                                                              1.429\*       0.592
                        Randomized                72 (83.7%)        44 (84.6%)                          
                        Non-randomized            1 (1.2%)          2 (3.8%)                            
                       Unknown                    13 (15.1%)        6 (11.5%)                           
  Intervention model                                                                      30.102\*      \<0.001
                        Crossover assignment      0 (0.0%)          2 (3.8%)                            
                        Factorial assignment      3 (3.5%)          0 (0.0%)                            
                        Parallel assignment       61 (70.9%)        40 (76.9%)                          
                        Sequential assignment     2 (2.3%)          9 (17.3%)                           
                        Single group assignment   20 (23.3%)        0 (0.0%)                            
                       Unknown                    0 (0.0%)          1 (0.9%)                            
  Masking                                                                                 8.101\*       0.127
                       Single                     7 (8.1%)          11 (21.2%)                          
                       Double                     14 (16.3%)        11 (21.2%)                          
                       Triple                     9 (10.5%)         3 (5.8%)                            
                       Quadruple                  24 (27.9%)        10 (19.2%)                          
                       None (open label)          32 (37.2%)        16 (30.8%)                          
                       Unknown                    0 (0.0%)          1 (1.9%)                            
  Phases                                                                                  44.375\*      \<0.001
                       Phase 1                    12 (14.0%)        6 (11.5%)                           
                       Phase 1\|phase 2           3 (3.5%)          4 (7.7%)                            
                       Phase 2                    34 (49.5%)        7 (13.5%)                           
                       Phase 3                    26 (30.2%)        4 (7.7%)                            
                       Phase 4                    11 (12.8%)        21 (40.4%)                          
                       Not applicable             0 (0.0%)          10 (19.2%)                          
  Enrollment                                                                              13.608\*      0.005
                       \<=50                      6 (7.0%)          12 (23.1%)                          
                       50--100                    17 (19.8%)        6 (11.5%)                           
                       100--500                   26 (30.2%)        21 (40.4%)                          
                       \>=500                     37 (43.0%)        12 (23.1%)                          
                       Unknown                    0 (0.0%)          1 (1.9%)                            

\*Fisher exact test.

Trials' Characteristics by Vaccine Intervention {#s3_5}
-----------------------------------------------

The trial characteristics of vaccine trials and non-vaccine trials are presented in [**Table 4**](#T4){ref-type="table"}. A total of 80.4% (N=111) of trials focused on vaccines. Among them, 78 trials investigated influenza vaccines, 16 trials investigated vaccines for pneumococcal diseases, and 17 trials investigated vaccines for other diseases, including herpes zoster, *C. difficile*-associated disease, tetanus, diphtheria, and Japanese encephalitis. Non-vaccine trials included antimicrobial trials (N=9), vitamin trials (N=5), probiotics trials (N=6), and other trials (N=7). A total of 53.8% non-vaccine trials were prevention-focused, and 34.6% trials were treatment-focused. Vaccine-related trials mostly began during 2007--2012 and non-vaccine trials mostly began during 2012--2017. A total of 36.9% vaccine trials had available results, while only 11.1% non-vaccine trials had available results. Trials tended to be larger in vaccine trials than non-vaccine trials. The industry was the primary lead sponsor for vaccine trials, and university was the lead sponsor for non-vaccine trials. Overall, compare with non-vaccine trials, vaccine trials had higher percentages of available study results, leading industry sponsor and viral etiology studies.

###### 

Characteristics of vaccine and non-vaccine trials.

  Variable             Subgroup                 Vaccine      Non-vaccine   χ^2^/Fisher   *P* value
  -------------------- ------------------------ ------------ ------------- ------------- -----------
  Year                                                                     2.803\*       0.421
                       Prior to 2007            17 (15.3%)   6 (22.2%)                   
                       2007--2012               43 (38.7%)   7 (25.9%)                   
                       2012--2017               37 (33.3%)   12 (44.4%)                  
                       2017--now                14 (12.6%)   2 (7.4%)                    
  Status                                                                   3.456\*       0.751
                       Active, not recruiting   11 (9.9%)    2 (7.4%)                    
                       Completed                85 (76.6%)   20 (74.1%)                  
                       Recruiting               6 (5.4%)     2 (7.4%)                    
                       Suspended                1 (0.9%)     0 (0.0%)                    
                       Terminated               2 (1.8%)     1 (3.7%)                    
                       Unknown status           5 (4.5%)     1 (3.7%)                    
                       Withdrawn                1 (0.9%)     1 (3.7%)                    
  Study results                                                            6.670         0.011
                       Has results              41 (36.9%)   3 (11.1%)                   
                       No results available     70 (63.1%)   24 (88.9%)                  
  Lead sponsor                                                             24.400\*      \<0.001
                       University               10 (9.0%)    10 (37.0%)                  
                       Hospital                 7 (6.3%)     7 (25.9%)                   
                       Industry                 84 (75.7%)   8 (29.6%)                   
                       Other                    10 (9.0%)    2 (7.4%)                    
  Funded by                                                                22.864\*      \<0.001
                       Industry                 79 (71.2%)   7 (25.9%)                   
                       NIH                      6 (5.4%)     0 (0.0%)                    
                       Other                    26 (23.4%)   20 (74.1%)                  
  Locations                                                                7.695\*       0.078
                       Asia                     15 (13.5%)   1 (3.7%)                    
                       Europe                   33 (29.7%)   9 (33.3%)                   
                       North America            59 (53.2%)   14 (51.9%)                  
                       Oceania                  4 (3.6%)     1 (3.7%)                    
                       South America            0 (0.0%)     2 (7.4%)                    
  Microbial etiology                                                       32.107\*      \<0.001
                       Viral                    87 (78.4%)   11 (40.7%)                  
                       Bacterial                24 (21.6%)   7 (25.9%)                   
                       Parasite                 0 (0.0%)     1 (3.7%)                    
                       Unknown                  0 (0.0%)     8 (29.6%)                   

\*Fisher exact test.

Trial Characteristics With Available Results {#s3_6}
--------------------------------------------

Among the 138 trials, 44 trials reported results on website and 94 trials did not. Among the 44 trials, 22 trials published 28 peer-reviewed papers. The summarized characteristics of the 22 published trials are shown in [**Table 5**](#T5){ref-type="table"}, and the details of the 22 published trials are shown in [**Supplement Table A**](#SM1){ref-type="supplementary-material"}. Two trials started before 2007, 13 trials began during 2007--2012, seven trials began during 2012--2017. Lead sponsors of trials were as follows: industry (72.7%), university (13.6%), and hospital (9.1%). The locations of countries were USA (86.4%), followed by Japan (9.1%) and Netherlands (1.0%). Fourteen trials were for viral pathogens (63.6%). Randomization (90.9%) was commonly used. More than half of trials were masked, and eight trials involved quadruple masking. Most trials were phase 3 (36.4%) and phase 4 (31.8%). Eleven trials (50.0%) recruited more than 500 participants, and eight trials (36.4%) recruited 100--500 participants, and the other three trials recruited less than 100 participants.

###### 

Characteristics of the 22 trials published results.

  Variable             Subgroup                   N (%)
  -------------------- -------------------------- ------------
  Year                                            
                       Prior to 2007              2 (9.1%)
                       2007--2012                 13 (59.1%)
                       2012--2017                 7 (31.8%)
  Lead sponsor                                    
                       University                 3 (13.6%)
                       Hospital                   2 (9.1%)
                       Industry                   16 (72.7%)
                       Other                      1 (4.5%)
  Funded by                                       
                       Industry                   16 (72.7%)
                       Other                      6 (27.3%)
  Locations                                       
                       Japan                      2 (9.1%)
                       Netherlands                1 (4.5%)
                       USA                        19 (86.4%)
  Microbial etiology                              
                       Viral                      14 (63.6%)
                       Bacterial                  7 (31.8%)
                       Unknown                    1 (4.5%)
  Primary purpose                                 
                        Prevention                21 (95.5%)
                        Other                     1 (4.5%)
  Allocation                                      
                        Randomized                20 (90.9%)
                       Unknown                    2 (9.1%)
  Intervention model                              
                        Parallel assignment       20 (90.9%)
                        Single group assignment   2 (9.1%)
  Masking                                         
                       Single                     3 (13.6%)
                       Double                     1 (4.5%)
                       Triple                     2 (9.1%)
                       Quadruple                  8 (36.4%)
                       None (open label)          8 (36.4%)
  Phases                                          
                       Phase 1                    1 (4.5%)
                       Phase 2                    5 (22.7%)
                       Phase 3                    8 (36.4%)
                       Phase 4                    7 (31.8%)
                       Not Applicable             1 (4.5%)
  Enrollment                                      
                       \<=50                      2 (9.1%)
                       50--100                    1 (4.5%)
                       100--500                   8 (36.4%)
                       \>=500                     11 (50.0%)

Discussion {#s4}
==========

Clinical trials play important roles in clinical practice and decision-making ([@B20]). Treatment of infectious diseases in old populations to reduce morbidity and mortality depends on well-designed trials. Interventional clinical trials for infectious diseases in old population have arisen much attention in recent years ([@B16]; [@B8]), however, little is known about the characteristics of registered clinical trials regarding this field. To the best of our knowledge, our study is the first to report registered trials in such field, and the results will provide the basis of the characteristics of trials design, location, and sponsor in this field.

Our study found that the number of trials explicitly designed to investigate interventions for old populations with infectious diseases was relatively small. Thus, evidence for old populations was lacking, and only a few trials were explicitly designed for this population ([@B5]; [@B3]; [@B2]; [@B22]). It is important to address that old populations are likely to be excluded from infectious disease trials than non-infectious disease trials ([@B11]). The reason might be that it was difficult to enroll enough old patients in trials, or low drug profit margins ([@B11]). With the accelerating of ageing progress, it is urgent to start more trials in old populations to provide evidence for clinical practice.

In our study, most trials were focusing on prevention strategies ([@B11]), which was quite different from trials in younger populations. Vaccinations for influenza and pneumonia were most frequently assessed. The overrepresentation of vaccine trials was influenced by the fact that most trials were performed in the US. Influenza and pneumonia were the most common infectious diseases in the US, and vaccination programs form part of routine clinical care in that country ([@B15]). Compared with high-income countries, old populations in low- and middle-income countries suffered the heavier burden of infectious diseases ([@B19]), including diarrhea, HIV/AIDS, tuberculosis, and malaria; however, there were not so many trials from low- and middle-income countries. Thus, it is suggested that high-income countries help low- and middle-income countries to conduct more trials. Another reason may be that trials from low- and middle-income countries are registered in other registries.

In our study, although 18.1% of trials were in phase 1 or phase 1/phase 2, only a few of them investigated novel drugs, despite increasing antimicrobial resistance. In addition, well-designed and adequately conducted trials were regarded as the best source of evidence. Randomization, blinding, and an appropriate patient population were the hallmarks of high-quality trials ([@B24]). In our study, most trials were randomized, masked, parallel assignment, and had a large enrollment, suggesting good quality of the included trials. Providing trials' results was more and more important. In our study, although 76.1% trials were completed, only 31.9% provided results on the database, the low percentage of available results was consistent with results in previous study ([@B24]). In addition, there was an increasing concern of industry role in trial design, conduct, and funding ([@B13]). A total of 62.3% trials were funded by industry, which was much more than drug control and prevention of ventilator-associated pneumonia ([@B6]), suggesting the lack of other sources of funding in interventional clinical trials on infectious diseases in old populations. Study designs between industry-funded trials and non-industry-funded infectious disease trials were similar. Compared with non-industry-funded trials, industry-funded trials had a higher proportion of trials with available results and a larger enrollment. Most trials were funded by large pharmaceutical companies, which had better financial and organizational resources and more experts in conducting trials ([@B14]). Our study revealed that vaccine trials had higher percentages of study results, leading industry sponsor and viral etiology trials, which suggested more treatment trials should be performed in this field.

There are several limitations to our study. First, [ClinicalTrials.gov](ClinicalTrials.gov) is the largest trial registry in the world, containing more than 80% of all trials in the World Health Organization International Clinical Trials Registry Platform. However, we could not exclude the possibility that some trials are registered in other trial registries. Second, our study is only a cross-sectional study, which limits our further analysis of potential influential factors. Third, as [ClinicalTrials.gov](ClinicalTrials.gov) is not designed to support for data analysis, it limits us to perform data synthesis; with the development of technology, researches can be combined by using data from different trials for the same topic.

In conclusion, this study provides useful information about registered interventional clinical trials on infectious diseases in old populations; this analysis will potentially help stakeholders, including investigators, academic centers, and industry to take future decisions regarding the conduct of clinical trials in this population. Additional and better trials are needed to provide more evidence.
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